Cargando…

Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1

Familial hemiplegic migraine type-1 (FHM-1) is a form of migraine with aura caused by mutations in the P/Q-type (Cav2.1) voltage-gated calcium channel. Pregabalin, used clinically in the treatment of chronic pain and epilepsy, inhibits P/Q-type calcium channel activity and recent studies suggest tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Cain, Stuart M., Alles, Sascha R. A., Gopaul, Ray, Bernier, Louis-Philippe, Yung, Andrew C., Bauman, Andrew, Yang, Yi, Baker, Glen B., Kozlowski, Piotr, MacVicar, Brian A., Snutch, Terrance P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623724/
https://www.ncbi.nlm.nih.gov/pubmed/37924146
http://dx.doi.org/10.1186/s13041-023-01062-6
_version_ 1785130794948231168
author Cain, Stuart M.
Alles, Sascha R. A.
Gopaul, Ray
Bernier, Louis-Philippe
Yung, Andrew C.
Bauman, Andrew
Yang, Yi
Baker, Glen B.
Kozlowski, Piotr
MacVicar, Brian A.
Snutch, Terrance P.
author_facet Cain, Stuart M.
Alles, Sascha R. A.
Gopaul, Ray
Bernier, Louis-Philippe
Yung, Andrew C.
Bauman, Andrew
Yang, Yi
Baker, Glen B.
Kozlowski, Piotr
MacVicar, Brian A.
Snutch, Terrance P.
author_sort Cain, Stuart M.
collection PubMed
description Familial hemiplegic migraine type-1 (FHM-1) is a form of migraine with aura caused by mutations in the P/Q-type (Cav2.1) voltage-gated calcium channel. Pregabalin, used clinically in the treatment of chronic pain and epilepsy, inhibits P/Q-type calcium channel activity and recent studies suggest that it may have potential for the treatment of migraine. Spreading Depolarization (SD) is a neurophysiological phenomenon that can occur during migraine with aura by propagating a wave of silenced neuronal function through cortex and sometimes subcortical brain structures. Here, utilizing an optogenetic stimulation technique optimized to allow for non-invasive initiation of cortical SD, we demonstrate that chronic pregabalin administration [12 mg/kg/day (s.c.)] in vivo increased the threshold for cortical spreading depolarization in transgenic mice harboring the clinically-relevant Ca(v)2.1(S218L) mutation (S218L). In addition, chronic pregabalin treatment limited subcortical propagation of recurrent spreading depolarization events to the striatum and hippocampus in both wild-type and S218L mice. To examine contributing underlying mechanisms of action of chronic pregabalin, we performed whole-cell patch-clamp electrophysiology in CA1 neurons in ex vivo brain slices from mice treated with chronic pregabalin vs vehicle. In WT mice, chronic pregabalin produced a decrease in spontaneous excitatory postsynaptic current (sEPSC) amplitude with no effect on frequency. In contrast, in S218L mice chronic pregabalin produced an increase in sEPSC amplitude and decreased frequency. These electrophysiological findings suggest that in FHM-1 mice chronic pregabalin acts through both pre- and post-synaptic mechanisms in CA1 hippocampal neurons to elicit FHM-1 genotype-specific inhibitory action. The results highlight the potential of chronic pregabalin to limit recurrent SD to subcortical brain structures during pathophysiological events in both the genetically-normal and FHM-1 brain. The work further provides insights into FHM-1 pathophysiology and the potential for chronic pregabalin treatment to prevent SD in migraineurs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13041-023-01062-6.
format Online
Article
Text
id pubmed-10623724
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106237242023-11-04 Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1 Cain, Stuart M. Alles, Sascha R. A. Gopaul, Ray Bernier, Louis-Philippe Yung, Andrew C. Bauman, Andrew Yang, Yi Baker, Glen B. Kozlowski, Piotr MacVicar, Brian A. Snutch, Terrance P. Mol Brain Research Familial hemiplegic migraine type-1 (FHM-1) is a form of migraine with aura caused by mutations in the P/Q-type (Cav2.1) voltage-gated calcium channel. Pregabalin, used clinically in the treatment of chronic pain and epilepsy, inhibits P/Q-type calcium channel activity and recent studies suggest that it may have potential for the treatment of migraine. Spreading Depolarization (SD) is a neurophysiological phenomenon that can occur during migraine with aura by propagating a wave of silenced neuronal function through cortex and sometimes subcortical brain structures. Here, utilizing an optogenetic stimulation technique optimized to allow for non-invasive initiation of cortical SD, we demonstrate that chronic pregabalin administration [12 mg/kg/day (s.c.)] in vivo increased the threshold for cortical spreading depolarization in transgenic mice harboring the clinically-relevant Ca(v)2.1(S218L) mutation (S218L). In addition, chronic pregabalin treatment limited subcortical propagation of recurrent spreading depolarization events to the striatum and hippocampus in both wild-type and S218L mice. To examine contributing underlying mechanisms of action of chronic pregabalin, we performed whole-cell patch-clamp electrophysiology in CA1 neurons in ex vivo brain slices from mice treated with chronic pregabalin vs vehicle. In WT mice, chronic pregabalin produced a decrease in spontaneous excitatory postsynaptic current (sEPSC) amplitude with no effect on frequency. In contrast, in S218L mice chronic pregabalin produced an increase in sEPSC amplitude and decreased frequency. These electrophysiological findings suggest that in FHM-1 mice chronic pregabalin acts through both pre- and post-synaptic mechanisms in CA1 hippocampal neurons to elicit FHM-1 genotype-specific inhibitory action. The results highlight the potential of chronic pregabalin to limit recurrent SD to subcortical brain structures during pathophysiological events in both the genetically-normal and FHM-1 brain. The work further provides insights into FHM-1 pathophysiology and the potential for chronic pregabalin treatment to prevent SD in migraineurs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13041-023-01062-6. BioMed Central 2023-11-03 /pmc/articles/PMC10623724/ /pubmed/37924146 http://dx.doi.org/10.1186/s13041-023-01062-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cain, Stuart M.
Alles, Sascha R. A.
Gopaul, Ray
Bernier, Louis-Philippe
Yung, Andrew C.
Bauman, Andrew
Yang, Yi
Baker, Glen B.
Kozlowski, Piotr
MacVicar, Brian A.
Snutch, Terrance P.
Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1
title Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1
title_full Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1
title_fullStr Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1
title_full_unstemmed Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1
title_short Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1
title_sort chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623724/
https://www.ncbi.nlm.nih.gov/pubmed/37924146
http://dx.doi.org/10.1186/s13041-023-01062-6
work_keys_str_mv AT cainstuartm chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT allessaschara chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT gopaulray chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT bernierlouisphilippe chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT yungandrewc chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT baumanandrew chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT yangyi chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT bakerglenb chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT kozlowskipiotr chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT macvicarbriana chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1
AT snutchterrancep chronicpregabalintreatmentprotectsagainstspreadingdepolarizationandaltershippocampalsynapticcharacteristicsinamodeloffamilialhemiplegicmigrainetype1